|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salehi F, Dunfield L, Phillips KP, Krewski
D and Vanderhyden BC: Risk factors for ovarian cancer: An overview
with emphasis on hormonal factors. J Toxicol Environ Health B Crit
Rev. 11:301–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bristow RE and Chi DS: Platinum-based
neoadjuvant chemotherapy and interval surgical cytoreduction for
advanced ovarian cancer: A meta-analysis. Gynecol Oncol.
103:1070–1076. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pignata S, C Cecere S, Du Bois A, Harter P
and Heitz F: Treatment of recurrent ovarian cancer. Ann Oncol. 28
(Suppl 8):viii51–viii6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bookman MA: Optimal primary therapy of
ovarian cancer. Ann Oncol. 27 (Suppl 1):i58–i62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balci S, Ayaz L, Gorur A, Yildirim Yaroglu
H, Akbayir S, Dogruer Unal N, Bulut B, Tursen U and Tamer L:
microRNA profiling for early detection of nonmelanoma skin cancer.
Clin Exp Dermatol. 41:346–351. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greenawalt EJ, Edmonds MD, Jain N, Adams
CM, Mitra R and Eischen CM: Targeting of SGK1 by miR-576-3p
Inhibits Lung Adenocarcinoma Migration and Invasion. Mol Cancer
Res. 17:289–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meng FM, Meng FM and Song XL: MiR-576-3p
is a novel marker correlated with poor clinical outcome in bladder
cancer. Eur Rev Med Pharmacol Sci. 21:973–977. 2017.PubMed/NCBI
|
|
12
|
Port M, Glaesener S, Ruf C, Riecke A,
Bokemeyer C, Meineke V, Honecker F and Abend M: Micro-RNA
expression in cisplatin resistant germ cell tumor cell lines. Mol
Cancer. 10:522011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lv J, Xia K, Xu P, Sun E, Ma J, Gao S,
Zhou Q, Zhang M, Wang F, Chen F, et al: miRNA expression patterns
in chemoresistant breast cancer tissues. Biomed Pharmacother.
68:935–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Wu WKK, Gao J, Li Z, Dong B, Lin
X, Li Y, Li Y, Gong J, Qi C, et al: Autophagy inhibition enhances
PD-L1 expression in gastric cancer. J Exp Clin Cancer Res.
38:1402019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wyss J, Dislich B, Koelzer VH, Galván JA,
Dawson H, Hädrich M, Inderbitzin D, Lugli A, Zlobec I and Berger
MD: Stromal PD-1/PD-L1 expression predicts outcome in colon cancer
patients. Clin Colorectal Cancer. 18:e20–e38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rojkó L, Reiniger L, Téglási V, Fábián K,
Pipek O, Vágvölgyi A, Agócs L, Fillinger J, Kajdácsi Z, Tímár J, et
al: Chemotherapy treatment is associated with altered PD-L1
expression in lung cancer patients. J Cancer Res Clin Oncol.
144:1219–1226. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cai J, Qi Q, Qian X, Han J, Zhu X, Zhang Q
and Xia R: The role of PD-1/PD-L1 axis and macrophage in the
progression and treatment of cancer. J Cancer Res Clin Oncol.
145:1377–1385. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang Z, Yang Y, Yang Y, Zhang Y, Yue Z,
Pan Z and Ren X: Ginsenoside Rg3 attenuates cisplatin resistance in
lung cancer by downregulating PD-L1 and resuming immune. Biomed
Pharmacother. 96:378–383. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zuo Y, Zheng W, Liu J, Tang Q, Wang SS and
Yang XS: MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance
of ovarian cancer cells. Neoplasma. 67:93–101. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sherr CJ: G1 phase progression: Cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu J, Fang Y, Cao Y, Qin R and Chen Q:
miR-449a Regulates proliferation and chemosensitivity to cisplatin
by targeting cyclin D1 and BCL2 in SGC7901 cells. Dig Dis Sci.
59:336–345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Biliran H Jr, Wang Y, Banerjee S, Xu H,
Heng H, Thakur A, Bollig A, Sarkar FH and Liao JD: Overexpression
of cyclin D1 promotes tumor cell growth and confers resistance to
cisplatin-mediated apoptosis in an elastase-myc
transgene-expressing pancreatic tumor cell line. Clin Cancer Res.
11:6075–6086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu R, Guo H and Lu S: MiR-335-5p restores
cisplatin sensitivity in ovarian cancer cells through targeting
BCL2L2. Cancer Med. 7:4598–4609. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zou J, Liu L, Wang Q, Yin F, Yang Z, Zhang
W and Li L: Downregulation of miR-429 contributes to the
development of drug resistance in epithelial ovarian cancer by
targeting ZEB1. Am J Transl Res. 9:1357–1368. 2017.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals. Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press (US); Washington, DC: 2011,
PubMed/NCBI
|
|
27
|
Wang H, Luo Y, Qiao T, Wu Z and Huang Z:
Luteolin sensitizes the antitumor effect of cisplatin in
drug-resistant ovarian cancer via induction of apoptosis and
inhibition of cell migration and invasion. J Ovarian Res.
11:932018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Joncourt F, Buser K, Altermatt H, Bacchi
M, Oberli A and Cerny T: Multiple drug resistance parameter
expression in ovarian cancer. Gynecol Oncol. 70:176–182. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kavallaris M, Kuo DY, Burkhart CA, Regl
DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial
ovarian tumors are associated with altered expression of specific
beta-tubulin isotypes. J Clin Invest. 100:1282–1293. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu DD, Li XS, Meng XN, Yan J and Zong ZH:
MicroRNA-873 mediates multidrug resistance in ovarian cancer cells
by targeting ABCB1. Tumour Biol. 37:10499–10506. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang H, Wang J, Cai K, Jiang L, Zhou D,
Yang C, Chen J, Chen D and Dou J: Downregulation of gene MDR1 by
shRNA to reverse multidrug-resistance of ovarian cancer A2780
cells. J Cancer Res Ther. 8:226–231. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang J, Dang F, Ren J and Wei W:
Biochemical aspects of PD-L1 regulation in cancer immunotherapy.
Trends Biochem Sci. 43:1014–1032. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hamanishi J, Mandai M, Matsumura N, Abiko
K, Baba T and Konishi I: PD-1/PD-L1 blockade in cancer treatment:
Perspectives and issues. Int J Clin Oncol. 21:462–473. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fournel L, Wu Z, Stadler N, Damotte D,
Lococo F, Boulle G, Ségal-Bendirdjian E, Bobbio A, Icard P,
Trédaniel J, et al: Cisplatin increases PD-L1 expression and
optimizes immune check-point blockade in non-small cell lung
cancer. Cancer Lett. 464:5–14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qie S and Diehl JA: Cyclin D1, cancer
progression, and opportunities in cancer treatment. J Mol Med
(Berl). 94:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Abdelrahman AE, Fathy A, Elsebai EA, Nawar
N and Etman WM: Prognostic impact of Apaf-1, Cyclin D1, and AQP-5
in serous ovarian carcinoma treated with the first-line
chemotherapy. Ann Diagn Pathol. 35:27–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liang Z, Li S, Xu X, Xu X, Wang X, Wu J,
Zhu Y, Hu Z, Lin Y, Mao Y, et al: MicroRNA-576-3p inhibits
proliferation in bladder cancer cells by targeting cyclin D1. Mol
Cells. 38:130–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu S, Chen S, Yuan W, Wang H, Chen K and
Li D and Li D: PD-1/PD-L1 interaction up-regulates MDR1/P-gp
expression in breast cancer cells via PI3K/AKT and MAPK/ERK
pathways. Oncotarget. 8:99901–99912. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Wang Q, Cui Y, Liu ZY, Zhao W,
Wang CL, Dong Y, Hou L, Hu G, Luo C, et al: Knockdown of cyclin D1
inhibits proliferation, induces apoptosis, and attenuates the
invasive capacity of human glioblastoma cells. J Neurooncol.
106:473–484. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dai J, Wei RJ, Li R, Feng JB, Yu YL and
Liu PS: A study of CCND1 with epithelial ovarian cancer cell
proliferation and apoptosis. Eur Rev Med Pharmacol Sci.
20:4230–4235. 2016.PubMed/NCBI
|
|
42
|
Xia B, Yang S, Liu T and Lou G: miR-211
suppresses epithelial ovarian cancer proliferation and cell-cycle
progression by targeting Cyclin D1 and CDK6. Mol Cancer. 14:572015.
View Article : Google Scholar : PubMed/NCBI
|
